Following Roma falsely representing Apex wasn’t a securities offering in 2019, BioLimitless’ doing the same with its “50% equity” passive returns investment scheme isn’t surprising.

Whether the SEC is investigating Roma as part of its Investview investigation or otherwise remains unclear.

Source: behindmlm.com